US5501954A - Method of detecting cellular material - Google Patents

Method of detecting cellular material Download PDF

Info

Publication number
US5501954A
US5501954A US08/259,224 US25922494A US5501954A US 5501954 A US5501954 A US 5501954A US 25922494 A US25922494 A US 25922494A US 5501954 A US5501954 A US 5501954A
Authority
US
United States
Prior art keywords
cells
cell
membrane filter
polymeric membrane
acid probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/259,224
Other languages
English (en)
Inventor
Anna M. Mahr
Ann E. Bowe
Alyson L. Ruff-Roberts
Katherine W. Klinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esoterix Genetic Laboratories LLC
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Assigned to GENZYME CORPORATION reassignment GENZYME CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOWE, ANN E., KLINGER, KATHERINE W., MAHR, ANNA M., RUFF-ROBERTS, ALYSON L.
Priority to US08/259,224 priority Critical patent/US5501954A/en
Priority to EP95923043A priority patent/EP0764218A4/fr
Priority to CA002192823A priority patent/CA2192823A1/fr
Priority to AU27726/95A priority patent/AU702236B2/en
Priority to JP8502395A priority patent/JPH10501419A/ja
Priority to PCT/US1995/007466 priority patent/WO1995034685A1/fr
Publication of US5501954A publication Critical patent/US5501954A/en
Application granted granted Critical
Assigned to ESOTERIX GENETIC LABORATORIES, LLC reassignment ESOTERIX GENETIC LABORATORIES, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GENZYME CORPORATION
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6841In situ hybridisation

Definitions

  • Fluorescence in situ hybridization is an important and powerful diagnostic tool that helps bridge the resolution gap between chromosome analysis and molecular techniques.
  • the ability to label DNA probe sets and to hybridize them to cytogenetic preparations demonstrates that this technology can be used to detect minute chromosomal abnormalities.
  • the high resolution of this technique allows direct visualization of single copy sequences. Because each chromosome occupies a distinct domain or discrete focal territory in the interphase nucleus (Lichter, P., et al., PNAS USA. 85:9664-9668, 1988; Manuelidis, L. Hum. Genet. 71:288-293, 1985; Cremer, T. et al., Exp. Cell Res.
  • a discrete FISH signal is obtained in most nuclei for each specific chromosome present. Therefore, an interphase nucleus with three copies of chromosome 13 will show three chromosome 13 FISH signals while a normal disomic nucleus will have 2 signals.
  • Appropriate probe sets based on cosmid contigs that are chromosome specific can be used to enumerate chromosomes in prenatal diagnostics. Trisomic karyotypes have been diagnosed by FISH procedures (Lichter, P., et al., PNAS USA. 85:9664-9668, 1988; Klinger, K., et al., Am. J. Hum. Genet. 51:55-65, 1992).
  • FISH Fluorescence In situ hybridization, FISH is frequently used in conjunction with chromosome analysis.
  • Most chromosome spreads analyzed in clinical laboratories are derived from abundant sources of artificially induced or naturally dividing cell types (e.g., lymphocytes, amniocytes, bone marrow).
  • the target cell is not abundant or if it is quiescent or infrequently dividing (e.g., rare cancer cells in Minimal Residual Disease or fetal cells in maternal cell circulation), more cells are accessible to analysis using interphase FISH than analysis based on chromosomes.
  • the method of the present invention relates to a rapid procedure for detecting DNA in a cell, while preserving the morphology of the nucleus for analysis.
  • the method comprises depositing a cell onto a polymeric membrane filter wherein the DNA contained in the cell is retained on the polymeric membrane filter and is available for binding with a fluorescently labeled nucleic acid probe, incubating the polymeric membrane filter with the labeled nulceic acid probe, and detecting the labeled nulceic acid probe wherein detection of the nulceic acid probe is indicative of the presence of the DNA.
  • the method is simple and quick and is applicable to the sample volumes found in clinical laboratories.
  • the method of the present invention allows for analysis with single copy sequence probes of cells, sorted onto, filtered onto, grown on or settled onto polymeric membrane filters.
  • the method allows for the hybridization of probes containing single copy or repetitive DNA sequences to metaphase chromosomes as well as to interphase nuclei on membrane filters.
  • the method of the present invention is based on the discovery that cells can be rapidly isolated, with the morphology of the nuclei substantially intact, for microscopic inspection and identification of the cell's DNA (i.e., target DNA, the DNA being analyzed).
  • the use of polymeric membrane filters has many advantages over glass slides, such as allowing the recovery of samples directly onto the membrane filter from a Fluorescence Activated Cell Sorter (FACS) while allowing for the simple removal of excess liquid along with the removal of fluorescent background due to the fluorescence-conjugated monoclonal on the cell surface. Filtration of cells onto membrane filters also reduces the need for centrifugation to concentrate cells.
  • polymeric membrane filters reduce the number of steps, when running single or multiple samples, required for analysis such as the need for various cell concentration steps (e.g., centrifugation) with the resultant loss of cells.
  • the method of the present invention is suitable for detecting the DNA of any cell. These include eukaryotic and prokaryotic cells.
  • the method of the present invention is used to detect the DNA of mammalian cells in a single cell suspension such as red cells, trophoblasts, leukocytes, amniocytes, tumor cells and blastomeres of humans and other mammals.
  • cells are deposited onto membranes by filtration. Cells can also be settled or grown onto membranes. The exact manner of cell deposition depends on the cell type and upon any previous treatment the cells have undergone.
  • cellular material refers to the components of a cell contained anywhere within a cell such as nucleic acids and proteins.
  • Cellular nucleic acids include DNA and RNA.
  • Cellular proteins include those contained in the nuclear matrix and cytoplasm, as well as nucleic acid associated proteins such as histones.
  • nuclear material refers to material contained anywhere in the nucleus of a cell, including nucleic acids and nuclear proteins.
  • cell suspension refers to any liquid containing cells. This includes cells that are normally in a single cell state i.e., are not normally adherent to other cells or part of a structure, tissue, organ. Such cells may be derived from blood or urine. "Cell suspension” also refers to disaggregated cells that originated from parts of structures, tissues or organs and are now suspended in liquid. “Cell suspensions” may contain either homogeneous or heterogeneous cell types that may or may not have originated from the same structure, tissue, organ or organism.
  • filtering refers to the application of a liquid sample, containing cells, to a polymeric membrane filter.
  • Filtering is the process of removing cells and/or parts of cells from excess fluid in a liquid sample by passing the sample through a microporous membrane filter. This process removes particles from solution by the use of pressure and retention on the filter.
  • Filtration is the process of physically removing suspended matter from a liquid by forcing the liquid through a porous mechanical barrier or membrane filter. This facilitates the extraction and analysis of the material separated from the fluid.
  • cell deposition or application includes filtering and other methods of applying single cells or single cell suspensions onto polymeric membrane filters. These other methods include putting a drop containing a single cell or single cell suspension onto a polymeric membrane filter and allowing it to dry. Another method includes settling (Klinger, K. et al, Am. J. Hum. Genet. 51:55-65, 1992).
  • polymeric membrane or "polymeric membrane filter” is intended to include organic membrane filters including those made of polycarbonate, polyvinylidene fluoride (PVDF), polysulfone, nylon, cellulosic esters, nitrocellulose, polypropylene and Teflon (PTFE), which have the characteristics of retaining DNA in suitable condition for hybridization, detection and analysis, while remaining intact through the in situ hybridization process.
  • PVDF polyvinylidene fluoride
  • PTFE Teflon
  • labeled ligand is intended to encompass antibodies and nucleic acids (or nucleic acid probes) labeled directly or indirectly with fluorescent dyes such as fluorescein isothiocyanate (FITC), Cy3TM, CyR0TM, Cy5TM (Biological Detection Systems, Inc., Pittsburgh, Pa.), Cascade BlueTM and Lucifer Yellow (Molecular Probes, Eugene, Oreg.).
  • fluorescent dyes such as fluorescein isothiocyanate (FITC), Cy3TM, CyR0TM, Cy5TM (Biological Detection Systems, Inc., Pittsburgh, Pa.), Cascade BlueTM and Lucifer Yellow (Molecular Probes, Eugene, Oreg.).
  • Labeled nucleic acid probes of the present invention may be labeled directly or indirectly with fluorescent dyes.
  • binding is intended to encompass the actions of which antibodies bind their targets and nucleic acids bind their targets, such as through hybridization.
  • the ligands of the present invention are labeled with biotin (bio) and are detected with fluorescently tagged avidin or streptavidin or are digoxigenin (dig) labeled probes, detected with fluorescently tagged anti-digoxigenin.
  • biotin biotin
  • dig digoxigenin
  • the DNA ligands can be directly labeled with fluorescent tags. These can be accomplished by standard procedures known by those of skill in the art.
  • detection is intended to encompass any method of detection where analysis or detection of the labeled-ligand bound cellular material (i.e., target DNA, etc.) is made possible with the aid of a device.
  • Such devices include microscopes, FACS devices and fluorimeter.
  • Digoxigenin-11-dUTP Boehringer Mannheim, Indianapolis, Ind.
  • biotin-16-dUTP Boehringer Mannheim, Indianapolis, Ind.
  • nick translation Rigby, et al., J. Mol. Biol., 113: 23, 1977
  • random priming Feinberg and Vogelstein, Anal. Biochem., 132:6-13,1983
  • Detection of compounds containing biotin can be accomplished by incubating with avidin conjugated to the fluorophore of choice.
  • Detection of dioxigenin-labeled nucleotides can be done with an anti-digoxigenin antibody conjugated to FITC, Texas Red, rhodamine or any other fluorophore. Monoclonal antibodies are often detected with secondary antibodies conjugated to the fluorophore of choice (FITC, Cy3TM, CyR0TM, rhodamine, Cascade BlueTM or Texas Red). Detection of DNA can be accomplished by staining with DNA binding dyes such as DAPI, acridine orange, propidium iodide, and Hoechst dyes. Other DNA binding dyes include those from Molecular Probes: YOYOTM, YO-PROTM, TOTOTM, TO-PROTM, and SYBRTM.
  • the method of the present invention comprises filtering the cells onto a polymeric membrane filter which is porous.
  • the membrane filters of the present invention may be placed onto an apparatus such as a scintered glass filter holder to maintain the rigidity of the membrane during filtering.
  • FISH results can vary, depending on the exact filter holder or device employed. It should be noted that a support made of CellMicroSievesTM (5 ⁇ m; Biodesign Inc. of New York, Carmel, N.Y.) inserted between the membrane filter and a vacuum device has been found to generally enhance the signal of the labeled ligand detected, and the morphology and distribution of the cellular material retained on the membrane filter. Additionally, a flatter filter can be obtained facilitating microscopic analysis. It is not absolutely necessary, and whether or not to include it in the protocol needs to be determined empirically.
  • any polymeric membrane filter which allows for the filtering of a liquid sample, containing cells or nuclei, and which retains the cellular material of the cell or the nuclei while allowing passage of the liquid portion of the sample and which allows for the subsequent microscopic detection of the retained cellular material without sufficient autofluorescence to interfere with analysis of the desired signal, is suitable in the method of the present invention.
  • the membrane must retain the cellular material through a series of treatments and washes and remain intact (i.e., not break apart). For example, some nitrocellulose membranes are too brittle for purposes of the present invention.
  • the nuclei that are retained must be in a morphological state suitable for microscopic analysis.
  • the membrane filter must also maintain its physical integrity throughout the procedure and remain relatively flat, i.e., not curl up and not dissolve in the reagents employed.
  • Such polymeric membrane filters in descending order of acceptability include those made of polycarbonate, polyvinylidene fluoride (PVDF), polysulfone, mixed esters of cellulose and nitrocellulose.
  • PVDF polyvinylidene fluoride
  • Some nylon membranes that were tried were unsuitable due to their autofluorescence. It should be noted that it has been found that membrane filters with a pore size of 5 ⁇ m or greater are not suitable for certain cells types because of their size, resulting in significant loss of cells. Membranes with pore sizes less than 0.1 ⁇ m tend to yield fragmented FISH signals with unfixed cells. Preparation of numerous samples is simplified and multiple membrane filters can be hybridized and washed simultaneously. These latter advantages are crucial for procedures in a clinical laboratory.
  • fixation procedures may be used in the method of the present invention. It should be noted that it has been discovered that certain fixation protocols appear to affect the quality of the signal analyzed or the nuclear morphology. Many fixatives have a detrimental effect on signal quality. Fixatives that have been found to have a beneficial effect include Streck's Tissue Fixative (S.T.F.TM; Streck Laboratories, Inc., Omaha, Nebr.), HistochoiceTM MB Fixative (Amresco, Solon, Ohio), RBC FixTM (Isolab, Inc., Akron, Ohio), and Zinc Formal-FixxTM (Shandon, Pittsburgh, Pa.). Other fixation methods such as microwaving are also amenable to FISH applications.
  • Some sample types do not require fixative treatment for good hybridization. Others require fixative treatment to preserve the nuclear morphology and to yield good hybridization signal.
  • the step at which a sample should be fixed needs to be determined empirically. After deposition onto filters, fixed or unfixed cells can still be responsive to reagents including NaOH, papain, and trypsin, and exhibit a change in nuclear morphology such as size. This may affect the hybridization results.
  • the DNA probes utilized were either single copy probes (100-140 kb) consisting of cosmid contigs or were repetitive probes.
  • the targets were nuclear DNA.
  • 13 and 21 cosmid contigs used we expect 2 signals for normal cells and 3-4 signals for aneuploid cells.
  • a 0.1 or 0.2 ⁇ m Costar (Cambridge, Mass.) polycarbonate membrane is placed over a 5 ⁇ m CellMicroSievesTM filter on a filter holder.
  • the filter holder a scintered glass type, is positioned on top of a vacuum flask.
  • Tubing connects the vacuum flask to a vacuum source via a vacuum regulator set at 400 mm Hg.
  • a cell suspension is pipetted onto the polycarbonate membrane. Once the fluid has passed through the membrane, the membrane filter is removed with forceps and air-dried.
  • the membrane can either be stored at -20° C. until hybridization or it can be hybridized on the same day.
  • the 0.1 or 0.2 ⁇ m black polycarbonate membrane filter can be used to collect samples sorted with a FACS.
  • the filter holder is placed on top of a plexiglass structure to which the vacuum hose is attached.
  • the entire device membrane filter, CellMicroSievesTM, filter holder, plexiglass structure
  • the membrane filter can be either dry or wet. If it is wet, the vacuum is withheld until the end of the sort.
  • the vacuum can be withheld until the end of the sort only if the liquid collecting on the membrane is not overly excessive.
  • the advantages of sorting cells directly onto a membrane filter instead of into a tube and then filtering the cells onto a membrane filter are that there is less cell loss, less sample handling and faster, easier sample processing.
  • the rate at which rare cells are sorted onto the membrane filter can affect the quality of the resulting FISH.
  • direct sorting onto dry membranes in the presence of a constant vacuum fetal liver cells sorted quickly (approximately 20 sec or less) onto the membrane yielded better results than the same cells deposited over a period of several minutes.
  • FISH FISH on membrane filters
  • analysis can take place either by a trained microscopist or by automated image processing. It is our goal to develop a FISH on membrane filters protocol that is totally compatible with automated image processing. This will necessitate making our samples as flat as possible. A three-dimensional target cell will render autofocusing a very difficult if not impossible task, and certainly complicates analysis even for a trained individual.
  • a preferred embodiment would be to have the cells and signals in a single focal plane. This also simplifies analysis if samples are manually read.
  • the method of the present invention consists of depositing a cell or cell suspension onto a polymeric membrane filter by vacuum filtration. No reagent treatment is needed to permeabilize the cells further. DNA probes to single copy sequences as well as to repetitive sequences have been used successfully to probe for nuclear DNA on interphase and metaphase chromosomes. Our method results in nuclei that are sufficiently flat for rapid microscopic enumeration of chromosomes. The entire protocol is simpler than that standardly employed in laboratories, and is amenable to rapid processing of a large number of clinical samples.
  • Human fetal liver cells were fractionated on a Ficoll-Paque gradient (Pharmacia, Uppsala, Sweden). Cells were diluted with 2 volumes of Hank's Balanced Salt Solution (HBSS) or PBS in a 50 ml conical tube. Ten ml of diluted blood was pipetted into a 15 ml conical tube and Ficoll-Paque in a 9 inch Pasteur pipette was then placed beneath the blood sample. Tubes were spun in a tabletop centrifuge at 2000 RPM for 20 minutes at 25° C. The top layer containing the serum was removed and discarded.
  • HBSS Hank's Balanced Salt Solution
  • the mononuclear cell layer was removed to a fresh tube, rinsed twice in PBS, resuspended in complete RPMI 1640 (RPMI 1640, 10% fetal calf serum (FCS), 1% penicillin, 1% streptamycin) and counted in a hemocytometer.
  • RPMI 1640 10% fetal calf serum (FCS), 1% penicillin, 1% streptamycin
  • Nucleated cell concentration was determined by spotting an aliquot onto either a 0.22 ⁇ m PVDF membrane filter (Millipore, Bedford, Mass.), or 0.1 or 0.2 ⁇ m polycarbonate membrane filter (Poretics, Livermore, Calif. or Costar, Cambridge, Mass.) and stained with a solution of DAPI antifade (500 ⁇ g/ml 4,6-diamidino-2-phenylindole (DAPI- Sigma, St. Louis, Mo.), 2.33% DABCO (Sigma, St. Louis Mo.), 20 mM Tris-HCl, pH 8.0, 90% v/v glyerol) to determine the number of nucleated cells. The number of DAPI-positive nuclei were then counted microscopically.
  • DAPI antifade 500 ⁇ g/ml 4,6-diamidino-2-phenylindole
  • DABCO Sigma, St. Louis Mo.
  • Cells were diluted in PBS to obtain a concentration of 100-400 cells/ ⁇ l and a minimum of 5-10 ⁇ l of cells were then vacuum filtered onto the membrane filters as follows.
  • the membrane filters were placed onto a dry 5 ⁇ m CellMicroSievesTM filter (Biodesign, Inc., Carmel, N.Y.) which was placed onto a scintered glass filtration apparatus (Kontes, Vineland, N.J.) and vacuum filtered at 400 mm Hg. Once the liquid had filtered through the membrane filters, the membrane was removed and air dried.
  • Membrane filters were stored at -20° C.
  • Ten ⁇ l of hybridization cocktail (50% formamide, 6X SSC, 10% dextran sulfate, 200 ng/ ⁇ l human Cot 1 DNA (GIBCO BRL, Life Technologies, Gathersburg, Md.), and 800 ng/ ⁇ l salmon sperm DNA which was sonicated for 600 bp fragments) was placed on the membrane filters.
  • a glass slide, parafilm or coverslip was placed over membrane filter.
  • a DNA probe was included in the hybridization cocktail at the following concentrations: 10 ng/ ⁇ l autosome probe, 0.5- 2.5 ng/ ⁇ l X probe or 5 ng/ ⁇ l Y probe. These probes and the protocol by which the probes were labeled are described in Klinger, K., eta/., Am. J. Hum. Genet., (1992) 51: 55.
  • the nucleic acids were denatured by incubating on a 80° C. slide warmer for 9-13 minutes.
  • the membrane filters were then incubated overnight at 37° C. in a humid chamber.
  • the membrane filters were removed from the slides, and rinsed twice in 2X SSC, pH 7.0, to remove excess hybridization cocktail.
  • the membrane filters were then washed in a batch process. The first 3 washes were for 5 minutes each at 42° C. in 50% formamide, 2XSSC, pH 7.0.
  • the membrane filters were rinsed twice in 2XSSC, washed 3 times for 5 minutes each in 0.1 XSSC at 60° C., blocked in 3% BSA, 4xSSC at 42° C. for 5 minutes . They were then mounted on slides and incubated for 30 minutes at 37° C.
  • bovine serum albumin BSA
  • Tween 20 with appropriate detection fluors: streptavidin-Cy3TM (2.0 ⁇ g/ml; Jackson ImmunoResearch Laboratories, Inc. West Grove, Pa.), anti-digoxigenin-FITC (1.0 ⁇ g/ml; Boehringer Mannhelm, Indianapolis, Ind.), CyROTM (250 ng/ml; Biological Detection Systems, Pittsburgh, Pa.) or avidin-FITC (5.0 ⁇ g/ml; Vector Laboratories, Burlingame, Calif.), and then covered with parafilm or a cover slip.
  • streptavidin-Cy3TM 2.0 ⁇ g/ml; Jackson ImmunoResearch Laboratories, Inc. West Grove, Pa.
  • anti-digoxigenin-FITC 1.0 ⁇ g/ml
  • CyROTM 250 ng/ml
  • Biological Detection Systems Pittsburgh, Pa.
  • avidin-FITC 5.0 ⁇ g/ml; Vector Laboratories, Burlingame, Calif
  • Membrane filters were then removed from slides and washed 3 times with 4XSSC 0.1% Tween 20 for 5 minutes at 42° C., rinsed in 2X SSC at room temperature, and placed on glass slides on which DAPI antifade had been placed. Approximately 25 ⁇ l DAPI antifade was placed on the membrane filters which were covered with a cover slip and sealed with nail polish.
  • Example 2 Female fetal liver mononuclear cells were obtained as described in Example 1 and prepared for fluorescence activated cell sorting (FACS). Cells were resuspended in 1 ml PBS supplemented with 1% BSA following fractionation on a Ficoll Hypaque gradient. From this 1 ml sample, a 50 ⁇ l aliquot was removed for staining with an antibody to keyhole limpet hemocyanin (Becton Dickinson, San Jose, Calif.) and 20 ⁇ l aliquots were removed and stained with each antibody to be used. These aliquots were used to determine blackground autofluorescence of the cells. The remainder of the sample was stained with FITC-anti-CD71 (Becton Dickinson, San Jose, Calif.).
  • FACS fluorescence activated cell sorting
  • Sorted cells were vacuum filtered (400 mm Hg) onto 0.2 ⁇ m black polycarbonate (Costar) membrane filters. After hybridization with BioX (2.5 ng/ ⁇ l) and simultaneously with Dig18 (10 ng/ ⁇ l), the two X signals were easily visible while the 18 signal were of moderate to weak strength.
  • Mononuclear human cord blood cells were separated on a Ficoll gradient and approximately 500 cells were vacuum filtered onto 0.22 ⁇ m PVDF (Millipore) membrane filters.
  • the filters were saturated with 75 mM KCl, incubated for 20 minutes at 37° C., and fixed for 10 minutes in 3:1 methanol:acetic acid. They were then dehydrated through an ethanol series (70%, 80%, 90%, 100%) for 30-60 seconds each. Filters were hybridized with 40 ⁇ l of hybridization cocktail containing either the BioX (2.5 ng/ ⁇ l), BioY (5 ng/ ⁇ l), Bio 13 (10 ng/ ⁇ l), Bio 18 (10 ng/ ⁇ l) or Bio21 (10 ng/ ⁇ l) probes. DNA was denatured for 10 minutes at 80° C., and the filters were hybridized overnight and washed as described in Example 1. There were good X and Y signals, and small sharp 13, 18 and 21 signals observed.
  • Mononuclear fetal liver cells prepared as described in Example 1 were vacuum filtered (400 mm Hg) onto different types of filters: mixed esters of cellulose (Millipore and Whatman), nitrocellulose (Schleicher and Schuell), PVDF (Millipore), polyfluorotetraethylene (PFTE: Millipore), nylon (Schleicher and Schuell and Micron Separations Inc.), polysulfone (Gelman), and polycarbonate (Costar). They were hybridized with either BioXDigY or DigXBio21. Hybridization signal quality from best to worst was as follows: polycarbonate, PVDF, polysulfone, mixed esters of cellulose, nitrocellulose, PFTE, and nylon.
  • a maternal blood sample consisting of 20 ml blood obtained from a donor about to undergo amniocentesis and who, based on ultrasound, was believed to be carrying a male fetus, was treated as described in Example 1.
  • Cells were stained by methods similar to those described in Example 2. The cells were stained with Hoechst 33342 for 30 minutes at 37° C., washed twice and then stained with monoclonal antibody conjugated to FITC. Cells were incubated at 4° C. for 45 minutes , washed twice and resuspended in 0.5 ml PBS.
  • Cells were sorted into 0.5 ml PBS/2% FCS and vacuum filtered onto two 0.1 ⁇ m black Costar polycarbonate membranes which were hybridized with BioXDigY probes. Of the two filters, the first contained 414 nuclei, of which 315 were XX, 5 were XY, and 72 were unknown.
  • Mononuclear fetal liver cells were recovered from a Ficoll gradient and stained with a proprietary monoclonal antibody and with antibody against CD3. They were sorted for the target of the monoclonal antibody and for absence of CD3 directly onto 0.22 ⁇ m PVDF (Millipore) and 0.2 ⁇ m polycarbonate (Poretics) membrane filters.
  • the filters were placed on a filter support derived from a disposable filter unit that had been dismantled. This filter support was placed onto an opening on a plexiglass device that also had an opening on the bottom to which a piece of tubing was connected. This tubing was attached to a house vacuum. This set up enabled us to vacuum filter the cells onto the membrane as they emerged from the sorter.
  • the membrane filters containing the cells were then processed in a variety of ways using various combinations of 100% ethanol, Optistain, 3:1 methanol:acetic acid or 75 mM KCl. Following processing, the membranes were then hybridized with BioXDig21 (X at 2.5 ng/ ⁇ l and 21 at 10 ng/ ⁇ l) and detected with Cy3TM as described in Example 1.
  • the best processing protocol for the 0.2 ⁇ m polycarbonate membrane was to sort onto a dry membrane, air dry, immerse for 1 minute in Hematic Optistain II-A buffer (Gam Rad, San Juan Capistrano, Calif.), dry and hybridize.
  • the best protocol for the 0.22 ⁇ m PVDF was the same as for the polycarbonate or to sort onto a dry membrane, immerse in 100% ethanol for 1 minute, Optistain for 1 minute, dry and hybridize. Best membranes had good strong Cy3TM and FITC signals, good nuclear morphology and were comparable to a good slide.
  • Male fetal liver cells had 1 X signal
  • female fetal liver cells had 2 X signals and cells from either gender had two 21 signals.
  • Mononuclear cells (Ficolled separately and then pooled) from 3 pregnant women were stained with CD71, Glycophorin A and Hoechst 33342.
  • a CellMicroSievesTM support filter was placed on the filter holder underneath the polycarbonate membrane. The cells were then sorted directly onto various dry polycarbonate membrane filters under constant (500 mm Hg) vacuum. Approximately 1,000 FACS events were sorted onto each membrane. The membranes were then hybridized with DigXBio13 and were then analyzed to determine which membranes exhibited the best signals.
  • the cell suspension was completely filtered onto the membrane, it was removed from the filtration apparatus and fixed postsort as shown in Table 2.
  • Cells from each presort fix condition were direct sorted onto 10 membrane filters, each of which was then treated with 1 of the postsort fix treatments.
  • the membrane filters were air dried and stored at -20° C. until hybridization.
  • Membranes were hybridized BioXDig21, and washed as described in Example 1. Samples were analyzed and the best from each presort fix group were then ranked on the strength and discreteness of the chromosome 21 signal and on nuclear morphology.
  • the best presort conditions were either no fix or 25 minutes S.T.F.TM.
  • the best postsort fixatives were 2, 15 and 30 minutes S.T.F.TM.
  • the worst postsort fixatives used in combination with a presort fix were: 2 and 12 minutes formaldehyde, 60 minutes S.T.F.TM and 15 minutes formaldehyde.
  • the best conditions contained cells with 2 strong, discrete chromosome 21 signals and 2 strong X signals.
  • the best conditions overall were: presort fixed with S.T.F.TM for 25 minutes and postsort fixed with S.T.F.TM for 2 minutes . Hybridization efficiency for the chromosome 21 probe was 100%.
  • the second best condition was unfixed presort and fixed with S.T.F.TM for 2 minutes postsort; compared to the best condition, the nuclear morphology in this sample was poorer and the hybridization efficiency was lower (96%) than with the best condition.
  • the next best conditions were 2 minutes paraformaldehyde presort fix plus 2 minutes S.T.F.TM postsort fix and 12 minutes paraformaldehyde presort fix with 2 minutes S.T.F.TM postsort fix.
  • Human male fetal liver cells were prepared as described in Example 1. Blood from 2 pregnant women was Ficolled separately and then pooled. Both the pooled maternal sample and the fetal liver sample were then separately stained with CD71, glycophorin A and Hoechst 33342 as described in Example 2. The cells were counted, and some of the fetal liver cells were then spiked into the maternal cells at a ratio of 1 fetal liver cell: 250 maternal cells. The fetal/maternal cell mixture as well as the pure maternal cell population were sorted using the Becton Dickinson Vantage FACS onto black 0.1 ⁇ m Costar polycarbonate membranes placed on the apparatus described in Example 7. A total of 1,500 FACS events were sorted onto each membrane. The vacuum pressure was set at 350 mm Hg. The membranes were hybridized with DigXBio18 according to the procedure detailed in Example 1.
  • the cells were sorted onto a polycarbonate membrane that was either dry (as in Examples 6-8) or wetted in various solutions (PBS, 2X PBS, 10% glycerol in PBS, 35 mM KCl, or nuclear isolation buffer (NIB; 250 mM sucrose, 25 mM NaCl, 10 mM PIPES, 1.5 mM MgCl 2 , 5 mM spermidine, pH 7.0 with HCl).
  • the vacuum was not turned on until the sort was completed.
  • the dry membranes one set was made with a continuous vacuum throughout the sort and the other set was made with no vacuum until the sort was completed.
  • the final variable tested was the presence or absence of a 5 ⁇ m CellMicroSievesTM membrane as a support. In those situations where the polycarbonate membranes were wet, the support membrane was also wetted with the same solution. A dry CellMicroSievesTM membrane was used when a dry polycarbonate membrane was placed onto the apparatus.
  • Membrane filters were analyzed for signal quality, nuclear background and nuclear morphology. For each wet/dry/vacuum condition, a determination was first made as to whether the presence or absence of a CellMicroSievesTM membrane was preferred. The seven membranes with the preferred CellMicroSievesTM configuration were then rated relative to each other. The spiked samples were analyzed by one individual and the maternal samples were analyzed by another individual. For the fetal liver/maternal spike, there was no consistent difference in signal or nuclear background observed in the 2 cell types. The lobular or irregular nuclei were usually maternal and the fetal nuclei tended to be round.
  • the DAPI-stained nuclei were larger and less bright, and there tended to be fewer irregularly shaped nuclei that stained unevenly with DAPI.
  • the sample application preferences for the spikes and maternal sample are detailed in Tables 3A and 3B.
  • Prewetting the filters affected the nuclear distribution. Nuclear background was affected by some of the solutions, such as the KCl and 2X PBS. Although a variety of cells were seen on most filters, there were some that yielded worse nuclei overall than others, e.g., NIB. When the hybridizations were optimal, there were 2 chromosome 18 signals for both the maternal and fetal cells. The male fetal cells contained 1 X chromosome signal and the adult female cells contained 2 X signals.
  • Mononuclear adult blood cells were recovered from a Ficoll gradient. Following determination of the nucleated cell concentration, the suspension was diluted to 200 cells/ ⁇ l and 5 ⁇ l was vacuum filtered onto 0.2 ⁇ m polycarbonate (Costar) membranes at 400 mm Hg. As described in Example 1, the membranes were then hybridized with XY probes (0.5 ng/ ⁇ l X and 5 ng/ ⁇ l Y) and washed. Fluorescence microscopy showed that the male adult cells contained an X and Y signal and the female adult cells contained two X signals.
  • XY probes 0.5 ng/ ⁇ l X and 5 ng/ ⁇ l Y
  • HEL cells were washed and resuspended in PBS. Cells were then vacuum filtered onto 0.2 ⁇ m black Costar polycarbonate membranes. The membranes were hybridized with BioXDigY and DigXBio21 as described in Example 1. The nuclei showed one X, two Y and four 21 signals or alternatively one X, one Y and four 21 signals.
  • Fetal liver samples were spotted in each quadrant of eleven 0.2 ⁇ m black Costar membrane filters. The membrane filters were then cut into 2 halves, each receiving two fetal liver sample sites. Each set of ten semicircular membrane filters was then stacked on top of each other and placed in a plastic bag. A total of 50 ⁇ l of hybridization cocktail containing Bio 13 (10 ng/ ⁇ l) and DigX probe (1.5 ng/ ⁇ l) was added to one bag prior to sealing. The second bag received 25 ⁇ l Of the same cocktail as well as 25 ⁇ l of wetting solution prior to sealing. DNA and probes on stacked membranes were denatured by placing bags in an 80° C. water bath for 10 minutes. The bags were then incubated at 37° C. overnight.
  • the eleventh membrane filter was split in half and both parts were hybridized according to our standard procedure detailed in Example 1. Both were placed on slides; one membrane was hybridized with 10 ⁇ l Of cocktail and the second was hybridized with 5 ⁇ l cocktail diluted with 5 ⁇ l of wetting solution. The membrane filters were then all washed by our standard protocol. Hybridization signal was detected by performing the detection step with all the membranes in a bag before being mounted individually on slides. The results were that the membrane filters in the center of each stack contained nuclei with X and 13 signals that were indistinguishable in strength and quality from membrane filters at the ends of the stack or from the membrane filter that was hybridized on a slide. In addition, the membrane filters with the more concentrated hybridization cocktail (i.e., without the wetting solution) gave a stronger hybridization signal.
  • a rectangular piece of black 0.2 ⁇ m Costar polycarbonate membrane filter was sandwiched into dot blot apparatus (96 Well Convertible Filtration Manifold System - GIBCO BRL). Twenty five ⁇ l of fetal cells resuspended in PBS was pipetted into each well, and vacuum (400 mm Hg) was applied to filter the cells onto the membrane. A CellMicroSievesTM 5 ⁇ m support filter was used under some of the polycarbonate membranes. Three different fetal liver samples were applied 24 times to each filter, such that the membrane containing 96 samples could be cut up into 24 sections, each section having 3 different fetal liver samples. Each section also had a site that was used for numbering membranes.
  • Protocol 1 Fetal liver mononuclear cells were diluted into PBS (20 cells/ ⁇ l) and 500 cells were vacuum filtered onto 0.2 ⁇ m white polycarbonate (Poretics),and 0.22 ⁇ m PVDF (Millipore) membranes. The membranes were then air dried prior to further processing through 1 of 3 protocols. Protocol 1 consisted of immmersing membranes sequentially for 2 minutes in 0.5M NaOH, neutralization buffer (1.5M NaCl. 0.5M Tris-HCl, pH 8.0), 2X SSC, and Optistain, then dried 5 minutes at 65° C. Protocol 2 membranes were immersed sequentially for 2 minutes in Optistain, 0.5M NaOH, and neutralization buffer, then dried for 5 minutes at 65° C.
  • Membranes for protocol 3 were immersed for 3 minutes in 0.5M NaOH, 2 minutes in neutralization buffer, 2 minutes in Optistain and then dried for 5 minutes at 65° C.
  • the Optistain control membranes were immersed in Optistain and then dried.
  • Membrane filters were then hybridized with BioXDig21.
  • For the PVDF membranes 30 ⁇ l of wetting solution and 30 ⁇ l hybridization cocktail was used, while the polycarbonate required 10 ⁇ l of wetting solution and 10 ⁇ l of hybridization cocktail. Denaturation was for 13 minutes at 80° C. Membranes were hybridized and washed as described in Example 1. The fluors used were anti-dig-FITC and avidin CyROTM.
  • Mononuclear cells from two cord bloods were each recovered from a Ficoll gradient, resuspended in RPMI 1640 medium containing fetal calf serum and then quantitated. Approximately 300 cells from cord blood sample #1 and 150 cells from cord blood #2 were filtered onto PVDF filters under 650 mm Hg of vacuum pressure and air dried. The same number of cells from each cord blood sample were cytospun (Cytospin 3, Shandon Lipshaw, Pittsburgh, Pa.) onto a glass microscope slides under the following conditions: 800 rpm, 5 minutes, low acceleration. The PVDF filters and glass microscope slides were stained with DAPI antifade and scored.
  • cord blood #1 the mean cell retention on PVDF filters was 353 cells (118%) as compared to the cell retention on the cytospun glass slides which was 165 cells (55%).
  • Cord blood #2 showed similiar results with the mean number of cell retained on PVDF filters being 147 (98%) as compared to the cell retention on the cytospun glass slides which was 103 (69%). Retention of cord blood cells was better when the cells were filtered onto PVDF membrane filters than when cytospun onto glass slides.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US08/259,224 1994-06-13 1994-06-13 Method of detecting cellular material Expired - Lifetime US5501954A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US08/259,224 US5501954A (en) 1994-06-13 1994-06-13 Method of detecting cellular material
JP8502395A JPH10501419A (ja) 1994-06-13 1995-06-13 細胞物質の検出方法
CA002192823A CA2192823A1 (fr) 1994-06-13 1995-06-13 Procede pour la detection de matieres cellulaires
AU27726/95A AU702236B2 (en) 1994-06-13 1995-06-13 Method of detecting cellular material
EP95923043A EP0764218A4 (fr) 1994-06-13 1995-06-13 Procede pour la detection de matieres cellulaires
PCT/US1995/007466 WO1995034685A1 (fr) 1994-06-13 1995-06-13 Procede pour la detection de matieres cellulaires

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/259,224 US5501954A (en) 1994-06-13 1994-06-13 Method of detecting cellular material

Publications (1)

Publication Number Publication Date
US5501954A true US5501954A (en) 1996-03-26

Family

ID=22984071

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/259,224 Expired - Lifetime US5501954A (en) 1994-06-13 1994-06-13 Method of detecting cellular material

Country Status (6)

Country Link
US (1) US5501954A (fr)
EP (1) EP0764218A4 (fr)
JP (1) JPH10501419A (fr)
AU (1) AU702236B2 (fr)
CA (1) CA2192823A1 (fr)
WO (1) WO1995034685A1 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153104A (en) * 1994-11-08 2000-11-28 Phoenix Medical Limited Body fluid separation means
US6281004B1 (en) * 1999-04-14 2001-08-28 Cytologix Corporation Quality control for cytochemical assays
FR2824144A1 (fr) * 2001-04-30 2002-10-31 Metagenex S A R L Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
US20020172950A1 (en) * 2000-06-02 2002-11-21 Daryn Kenny Highly sensitive gene detection and localization using in situ branched-DNA hybridization
US6506563B1 (en) * 1995-12-22 2003-01-14 Yale University Multiparametric fluorescence in situ hybridization
US20030166261A1 (en) * 1999-04-14 2003-09-04 Cytologix Corporation Quality control for cytochemical assays
US20030215841A1 (en) * 1995-09-15 2003-11-20 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US20040009473A1 (en) * 2002-06-07 2004-01-15 Christopher Pease Kit and process for microbiological for on-site examination of a liquid sample
US20070141723A1 (en) * 2005-12-16 2007-06-21 Sompuram Seshi A Immunohistochemistry staining controls
US7299805B2 (en) 2002-06-07 2007-11-27 Marctec, Llc Scaffold and method for implanting cells
US20080076111A1 (en) * 2006-09-22 2008-03-27 Dyn-Bioshaf (2006) Ltd. Methods and kits for determining sperm cell number
US20100021910A1 (en) * 2008-07-18 2010-01-28 Canon U.S. Life Sciences, Inc. Methods and Systems for Microfluidic DNA Sample Preparation
US20100184069A1 (en) * 2009-01-21 2010-07-22 Streck, Inc. Preservation of fetal nucleic acids in maternal plasma
US20100209930A1 (en) * 2009-02-18 2010-08-19 Streck, Inc. Preservation of cell-free nucleic acids
US20110014605A1 (en) * 2009-07-17 2011-01-20 Canon U.S. Life Sciences, Inc. Methods and systems for dna isolation on a microfluidic device
US20110111410A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in intact cells within a blood sample
US20110237459A1 (en) * 1995-04-25 2011-09-29 Nexus Biosystems, Inc. Multiplexed Assay Using Encoded Solid Support Matrices
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US10091984B2 (en) 2013-07-24 2018-10-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US10966421B2 (en) 2002-10-16 2021-04-06 Streck, Inc. Method and device for collecting and preserving cells for analysis
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US11299764B2 (en) 2015-11-20 2022-04-12 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US11506655B2 (en) 2016-07-29 2022-11-22 Streck, Inc. Suspension composition for hematology analysis control
US11788123B2 (en) 2017-05-26 2023-10-17 President And Fellows Of Harvard College Systems and methods for high-throughput image-based screening
US11959075B2 (en) 2014-07-30 2024-04-16 President And Fellows Of Harvard College Systems and methods for determining nucleic acids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499183A (en) * 1982-12-21 1985-02-12 Ortho Diagnostic Systems Inc. Detecting intracellular antigens in swelled and fixed cells with labeled antibody
US5187083A (en) * 1990-11-13 1993-02-16 Specialty Laboratories, Inc. Rapid purification of DNA
US5326691A (en) * 1991-11-21 1994-07-05 John Hozier Micro-libraries and methods of making and manipulating them methods for generating and analyzing micro-libraries
US5366867A (en) * 1992-04-01 1994-11-22 Nihon Millipore Kogyo Method of determining viable microbial cell count

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL62479A (en) * 1981-03-25 1984-11-30 Yeda Res & Dev Assay for the determination of carcinogenicity
WO1994002646A1 (fr) * 1992-07-17 1994-02-03 Aprogenex Inc. Enrichissement et identification de cellules foetales dans le sang maternel pour l'hybridation in situ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499183A (en) * 1982-12-21 1985-02-12 Ortho Diagnostic Systems Inc. Detecting intracellular antigens in swelled and fixed cells with labeled antibody
US5187083A (en) * 1990-11-13 1993-02-16 Specialty Laboratories, Inc. Rapid purification of DNA
US5326691A (en) * 1991-11-21 1994-07-05 John Hozier Micro-libraries and methods of making and manipulating them methods for generating and analyzing micro-libraries
US5366867A (en) * 1992-04-01 1994-11-22 Nihon Millipore Kogyo Method of determining viable microbial cell count

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
Bianchi, D. W. et al. (1987) "Direct Hybridization to DNA From Small Numbers of Flow-Sorted Nucleated Newborn Cells" Cytometry, 8:197-202.
Bianchi, D. W. et al. (1987) Direct Hybridization to DNA From Small Numbers of Flow Sorted Nucleated Newborn Cells Cytometry, 8:197 202. *
Brigati, D. J. et al. (1983) "Detection of Viral Genomes in Cultrued Cells and Paraffin-Embedded Tissue Sections Using Biotin-Labeled Hybridization Probes" VIROLOGY, 126:32-50.
Brigati, D. J. et al. (1983) Detection of Viral Genomes in Cultrued Cells and Paraffin Embedded Tissue Sections Using Biotin Labeled Hybridization Probes VIROLOGY, 126:32 50. *
Cremer, T. et al. (1988) "Rapid Interphase and Metaphase Assessment of Specific Chromosomal Changes in Neuroectodermal Tumor Cells by in Situ Hybridization with Chemically Modified DNA Probes" Experimental Cell Research, 176:199-200.
Cremer, T. et al. (1988) Rapid Interphase and Metaphase Assessment of Specific Chromosomal Changes in Neuroectodermal Tumor Cells by in Situ Hybridization with Chemically Modified DNA Probes Experimental Cell Research, 176:199 200. *
Johnson, C. V. et al. (1991) "Fluorescent Detection of Nuclear RNA and DNA: Implication for Genome Organization" Methods Cell Bio, vol. 35, Chap 3, pp. 73-99.
Johnson, C. V. et al. (1991) Fluorescent Detection of Nuclear RNA and DNA: Implication for Genome Organization Methods Cell Bio, vol. 35, Chap 3, pp. 73 99. *
Klinger, K. et al. (1992) "Rapid Detection of Chromosome Aneuploidies in Uncultured Amniocytes by Using Fluorescense In Situ Hybridization (FISH)" Am. J. Hum. Genet, 51:55-65.
Klinger, K. et al. (1992) Rapid Detection of Chromosome Aneuploidies in Uncultured Amniocytes by Using Fluorescense In Situ Hybridization (FISH) Am. J. Hum. Genet, 51:55 65. *
Landegent, J. E. et al. (1987) "Use of whole cosmid cloned genomic sequences for chromosomal localization by non-radioactive in situ hybridization" Hum Genet, 77:366-370.
Landegent, J. E. et al. (1987) Use of whole cosmid cloned genomic sequences for chromosomal localization by non radioactive in situ hybridization Hum Genet, 77:366 370. *
Lawrence, J. B. et al. (1988) "Sensitive, High Resolution Chromatin and Chromosome Mapping In Situ: Presence and Orientation of Two Closely Integrated Copies of EBV in a Lymphoma Line" Cell, 52:51-61.
Lawrence, J. B. et al. (1988) Sensitive, High Resolution Chromatin and Chromosome Mapping In Situ: Presence and Orientation of Two Closely Integrated Copies of EBV in a Lymphoma Line Cell, 52:51 61. *
Lawrence, J. B. et al. (1990) "Interphase and Metaphase Resolution of Different Distances Within the Human Dystophin Gene" SCIENCE, 249:928-932.
Lawrence, J. B. et al. (1990) Interphase and Metaphase Resolution of Different Distances Within the Human Dystophin Gene SCIENCE, 249:928 932. *
Levedakou et al, Biotechniques vol. 7(5) 442 447, 1989. *
Levedakou et al, Biotechniques vol. 7(5) 442-447, 1989.
Lichter, P. et al. (1988) "Rapid detection of human chromosome 21 aberrations by in situ hybridization" Proc. Natl. Acad. Sci., 85:9664-9668.
Lichter, P. et al. (1988) Rapid detection of human chromosome 21 aberrations by in situ hybridization Proc. Natl. Acad. Sci., 85:9664 9668. *
Melchers et al. J. of Clinical Microbiology 27(1)106 110, 1989. *
Melchers et al. J. of Clinical Microbiology 27(1)106-110, 1989.
Pinkel, D. et al. (1986) "Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization" Proc. Natl. Acad. Sci, 83:2934-2938.
Pinkel, D. et al. (1986) Cytogenetic analysis using quantitative, high sensitivity, fluorescence hybridization Proc. Natl. Acad. Sci, 83:2934 2938. *
Svoboda, K. K. H. (1991) "Intracellular localization of types I and II collagen mRNA and endoplasmic reticulum in embryotic corneal epithelia" Journal of Cell Science, 100:23-33.
Svoboda, K. K. H. (1991) Intracellular localization of types I and II collagen mRNA and endoplasmic reticulum in embryotic corneal epithelia Journal of Cell Science, 100:23 33. *
Tkachuk, D. C. et al. (1991) "Clinical Applications of Fluorescence in situ Hybridization" GATA, 8(2):67-74.
Tkachuk, D. C. et al. (1991) Clinical Applications of Fluorescence in situ Hybridization GATA, 8(2):67 74. *

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153104A (en) * 1994-11-08 2000-11-28 Phoenix Medical Limited Body fluid separation means
US6355174B1 (en) * 1994-11-08 2002-03-12 Phoenix Medical Limited Method of separating foetal trophoblasts from maternal blood
US20130090260A1 (en) * 1995-04-25 2013-04-11 Irori Technologies, Inc. Multiplexed Assay Using Spectrally-Encoded Solid Support Matrices
US8219327B2 (en) * 1995-04-25 2012-07-10 Irori Technologies, Inc. Multiplexed assay using encoded solid support matrices
US20110237459A1 (en) * 1995-04-25 2011-09-29 Nexus Biosystems, Inc. Multiplexed Assay Using Encoded Solid Support Matrices
US6927032B2 (en) * 1995-09-15 2005-08-09 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US20050158746A1 (en) * 1995-09-15 2005-07-21 Affymetrix Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US20050202500A1 (en) * 1995-09-15 2005-09-15 Affymetrix, Inc. Expression monitoring to high density oligonucleotide arrays
US20030215841A1 (en) * 1995-09-15 2003-11-20 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US6506563B1 (en) * 1995-12-22 2003-01-14 Yale University Multiparametric fluorescence in situ hybridization
US6548259B2 (en) * 1995-12-22 2003-04-15 Yale University Multiparametric fluorescence in situ hybridization
US7011940B1 (en) 1999-04-14 2006-03-14 Medical Discovery Partners Llc Quality control for cytochemical assays
US20030166261A1 (en) * 1999-04-14 2003-09-04 Cytologix Corporation Quality control for cytochemical assays
US6281004B1 (en) * 1999-04-14 2001-08-28 Cytologix Corporation Quality control for cytochemical assays
US6855490B2 (en) 1999-04-14 2005-02-15 Medical Discovery Partners Llc Method for attaching biological molecules to a glass surface
US20060127956A1 (en) * 1999-04-14 2006-06-15 Sompuram Seshi R Quality control for cytochemical assays
US20020172950A1 (en) * 2000-06-02 2002-11-21 Daryn Kenny Highly sensitive gene detection and localization using in situ branched-DNA hybridization
US7033758B2 (en) 2000-06-02 2006-04-25 Bayer Corporation Highly sensitive gene detection and localization using in situ branched-DNA hybridization
WO2002088736A3 (fr) * 2001-04-30 2003-09-25 Metagenex S A R L Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
US7651838B2 (en) 2001-04-30 2010-01-26 Institut National De La Sante Et De La Recherche Medicale Prenatal diagnosis method on isolated foetal cell of maternal blood
WO2002088736A2 (fr) * 2001-04-30 2002-11-07 Institut National De La Sante Et De La Recherche Medicale Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
US20050049793A1 (en) * 2001-04-30 2005-03-03 Patrizia Paterlini-Brechot Prenatal diagnosis method on isolated foetal cell of maternal blood
FR2824144A1 (fr) * 2001-04-30 2002-10-31 Metagenex S A R L Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
US7299805B2 (en) 2002-06-07 2007-11-27 Marctec, Llc Scaffold and method for implanting cells
US11613731B2 (en) 2002-06-07 2023-03-28 P Tech, Llc Scaffold and method for implanting cells
US10294455B2 (en) 2002-06-07 2019-05-21 P Tech, Llc Methods of building a body portion
US20080051624A1 (en) * 2002-06-07 2008-02-28 Bonutti Peter M Scaffold and method for implanting cells
US20040009473A1 (en) * 2002-06-07 2004-01-15 Christopher Pease Kit and process for microbiological for on-site examination of a liquid sample
US10966421B2 (en) 2002-10-16 2021-04-06 Streck, Inc. Method and device for collecting and preserving cells for analysis
US11647743B2 (en) 2002-10-16 2023-05-16 Streck Llc Method and device for collecting and preserving cells for analysis
US20070141723A1 (en) * 2005-12-16 2007-06-21 Sompuram Seshi A Immunohistochemistry staining controls
US20080076111A1 (en) * 2006-09-22 2008-03-27 Dyn-Bioshaf (2006) Ltd. Methods and kits for determining sperm cell number
US9513196B2 (en) 2008-07-18 2016-12-06 Canon U.S. Life Sciences, Inc. Methods and systems for microfluidic DNA sample preparation
US8313906B2 (en) * 2008-07-18 2012-11-20 Canon U.S. Life Sciences, Inc. Methods and systems for microfluidic DNA sample preparation
US20100021910A1 (en) * 2008-07-18 2010-01-28 Canon U.S. Life Sciences, Inc. Methods and Systems for Microfluidic DNA Sample Preparation
US20100184069A1 (en) * 2009-01-21 2010-07-22 Streck, Inc. Preservation of fetal nucleic acids in maternal plasma
US11634747B2 (en) 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
US8586306B2 (en) 2009-02-18 2013-11-19 Streck, Inc. Preservation of cell-free RNA in blood samples
US10294513B2 (en) 2009-02-18 2019-05-21 Streck, Inc. Preservation of cell-free nucleic acids
US9657227B2 (en) 2009-02-18 2017-05-23 Streck, Inc. Preservation of cell-free RNA in blood samples
US9926590B2 (en) 2009-02-18 2018-03-27 Streck, Inc. Devices and compositions for preservation of cell-free nucleic acids
US10689686B2 (en) 2009-02-18 2020-06-23 Streck, Inc. Preservation of cell-free nucleic acids
US8304187B2 (en) 2009-02-18 2012-11-06 Streck, Inc. Preservation of cell-free RNA in blood samples
US20180216165A1 (en) 2009-02-18 2018-08-02 Streck, Inc. Preservation of cell-free nucleic acids
US11761025B2 (en) 2009-02-18 2023-09-19 Streck Llc Preservation of cell-free nucleic acids
US10144955B2 (en) 2009-02-18 2018-12-04 Streck, Inc. Methods for preservation of cell-free nucleic acids
US20100209930A1 (en) * 2009-02-18 2010-08-19 Streck, Inc. Preservation of cell-free nucleic acids
US9116088B2 (en) 2009-07-17 2015-08-25 Canon U.S. Life Sciences, Inc. Methods and systems for DNA isolation on a microfluidic device
US20110014605A1 (en) * 2009-07-17 2011-01-20 Canon U.S. Life Sciences, Inc. Methods and systems for dna isolation on a microfluidic device
US9938519B2 (en) 2009-07-17 2018-04-10 Canon U.S. Life Sciences, Inc. Methods and systems for DNA isolation on a microfluidic device
US8304185B2 (en) * 2009-07-17 2012-11-06 Canon U.S. Life Sciences, Inc. Methods and systems for DNA isolation on a microfluidic device
US20110111410A1 (en) * 2009-11-09 2011-05-12 Streck, Inc. Stabilization of rna in intact cells within a blood sample
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US11547111B2 (en) 2013-07-24 2023-01-10 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US10674721B2 (en) 2013-07-24 2020-06-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US10091984B2 (en) 2013-07-24 2018-10-09 Streck, Inc. Compositions and methods for stabilizing circulating tumor cells
US12114654B2 (en) 2013-07-24 2024-10-15 Streck Llc Compositions and methods for stabilizing circulating tumor cells
US11959075B2 (en) 2014-07-30 2024-04-16 President And Fellows Of Harvard College Systems and methods for determining nucleic acids
US12104151B2 (en) 2014-07-30 2024-10-01 President And Fellows Of Harvard College Systems and methods for determining nucleic acids
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
US11299764B2 (en) 2015-11-20 2022-04-12 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
US11506655B2 (en) 2016-07-29 2022-11-22 Streck, Inc. Suspension composition for hematology analysis control
US11788123B2 (en) 2017-05-26 2023-10-17 President And Fellows Of Harvard College Systems and methods for high-throughput image-based screening

Also Published As

Publication number Publication date
EP0764218A1 (fr) 1997-03-26
JPH10501419A (ja) 1998-02-10
AU702236B2 (en) 1999-02-18
WO1995034685A1 (fr) 1995-12-21
EP0764218A4 (fr) 1999-09-01
AU2772695A (en) 1996-01-05
CA2192823A1 (fr) 1995-12-21

Similar Documents

Publication Publication Date Title
US5501954A (en) Method of detecting cellular material
US5629147A (en) Enriching and identifying fetal cells in maternal blood for in situ hybridization
CA2140278C (fr) Enrichissement et determination des cellules foetales dans le sang maternel pour hybridation in situ
US5750340A (en) In situ hybridization solution and process
US5756696A (en) Compositions for chromosome-specific staining
KR100523381B1 (ko) 태아 세포를 동정하는데 사용되는 항배아 헤모글로빈 항체
AU2002357588B2 (en) Blood cell separation system
EP1172445A1 (fr) Procede d'analyse genetique directe de cellules cible utilisant sondes fluorescentes
WO1995003431A1 (fr) Enrichissement et identification de cellules f×tales dans du sang maternel destinees a une hybridation in situ
US6210889B1 (en) Method for enrichment of fetal cells from maternal blood and use of same in determination of fetal sex and detection of chromosomal abnormalities
US6022689A (en) Situ hybridization slide processes
IE20070380A1 (en) Methods and compositions for chromosome-specific staining
Lomax et al. The utilization of interphase cytogenetic analysis for the detection of mosaicism
AU784952B2 (en) Methods for clinical diagnosis
WO1998015656A9 (fr) Procedes de preparation de lames porte-objet pour hybridation in situ
Orsetti et al. Fetal cells in maternal blood: the use of primed in situ (PRINS) labelling technique for fetal cell detection and sex assessment
Hamada et al. Mid‐trimester fetal sex determination from maternal peripheral blood by fluorescence in situ hybridization without enrichment of fetal cells
US5693783A (en) DNA probes for detecting the most common liveborn chromosomal aneuploidies
JP2000504213A (ja) 細胞内成分を用いる無傷細胞の固相強化
IL94906A (en) Methods and preparations for specific chromosome specification
Mahr et al. Fluorescence in situ hybridization of cells on polyvinylidene fluoride membrane filters
WO1999015892A1 (fr) Enrichissement du sang peripherique maternel en cellules trophoblastiques et identification desdites cellules
WO1992019967A1 (fr) Procede permettant d'obtenir des cellules porteuses d'informations
NZ245427A (en) Methods and compositions for chromosome-specific staining

Legal Events

Date Code Title Description
AS Assignment

Owner name: GENZYME CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHR, ANNA M.;BOWE, ANN E.;RUFF-ROBERTS, ALYSON L.;AND OTHERS;REEL/FRAME:007044/0881

Effective date: 19940610

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

REMI Maintenance fee reminder mailed
AS Assignment

Owner name: ESOTERIX GENETIC LABORATORIES, LLC, NORTH CAROLINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GENZYME CORPORATION;REEL/FRAME:025656/0581

Effective date: 20101130